Last quarter (Q ), Kiromic Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Kiromic Biopharma's net income was $-6.76M. See Kiromic Biopharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 10.62M	$ 31.11M	$ -25.74M	$ 19.20M	$ 3.71M	$ 3.18M
Operating Income	$ -24.47M	$ -31.11M	$ -25.31M	$ -19.20M	$ -3.71M	$ -3.18M
Net Non Operating Interest Income Expense	$ -161.00K	$ -166.50K	$ -12.20K	$ -3.30K	$ -22.50K	$ -633.10K
Other Income Expense	$ -3.48M	$ -12.80K	$ -159.20K	-	-	-
Pretax Income	$ -30.99M	$ -34.73M	$ -25.59M	$ -19.20M	$ -3.73M	$ -3.82M
Tax Provision	-	-	-	-	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -31.08M	$ -34.73M	$ -25.59M	$ -19.91M	$ -3.98M	$ -3.82M
Basic EPS	$ -72.04	$ -64.42	$ -67.82	$ -4.42	$ -1.06	$ -1.08
Diluted EPS	$ -72.04	$ -64.42	$ -67.82	$ -4.42	$ -1.06	$ -1.08
Basic Average Shares	$ 2.47M	$ 544.48K	$ 11.42M	$ 4.51M	$ 3.53M	$ 3.53M
Diluted Average Shares	$ 2.47M	$ 544.48K	$ 11.42M	$ 4.51M	$ 3.53M	$ 3.53M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 10.62M	$ 31.11M	$ -25.74M	$ 19.20M	$ 3.71M	$ 3.18M
Net Income From Continuing And Discontinued Operation	$ -30.99M	$ -34.73M	$ -25.59M	$ -19.20M	$ -3.73M	$ -3.82M
Normalized Income	$ -8.40M	-	-	$ -19.20M	$ -3.73M	$ -3.82M
Interest Expense	$ 1.40K	-	-	$ 3.30K	$ 22.50K	$ 633.10K
EBIT	$ -30.50M	$ -34.56M	$ -25.58M	$ -19.20M	$ -3.71M	$ -3.18M
EBITDA	$ -28.40M	$ -32.88M	$ -25.11M	$ -19.00M	$ -3.71M	$ -3.10M

Currency in USD

Kiromic Biopharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing